<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913547</url>
  </required_header>
  <id_info>
    <org_study_id>DO109828</org_study_id>
    <nct_id>NCT02913547</nct_id>
  </id_info>
  <brief_title>Silk'n HST for Wrinkle Reduction - Clinical Study Protocol</brief_title>
  <official_title>Safety, Efficacy and Usage Compliance of the Silk'n HST Home Use Device for Treating Periorbital Wrinkles and Improving Skin Appearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Home Skinovations Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Home Skinovations Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety, efficacy and usage compliance of the
      home-use device Silk'n HST for self-treatment of periorbital wrinkles and skin laxity and
      improvement of skin appearance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm prospective study of 18 weeks aimed to evaluate the safety and
      efficiency of Silk'n HST treatment on the periorbital areas. 30 subjects will be enrolled by
      a single USA clinical site. Throughout the trial there will be 3 pre-scheduled face to face
      treatment visits, as well as additional 18 independent treatments at home. 2 additional
      follow-up visits will be conducted 1 and 3 months following treatment end. In addition, 2
      maintenance treatment will be conducted independently at home once a month following
      treatment end.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of wrinkle severity according to the Fitzpatrick wrinkle scale</measure>
    <time_frame>18 weeks</time_frame>
    <description>measurements were accomplished via standardized photographs blinded evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>subjective wrinkle improvement as measured by satisfactory questionnaires</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.
Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silk'n HST</intervention_name>
    <description>Treatment with Silk'n HST on the periorbital area as instructed in the user's manual</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult subjects aged 35-65.

          2. The subjects should understand the information provided about the investigative nature
             of the treatment, possible benefits and side effects, and sign the Informed Consent
             Form, including the permission to use photography (forms attached).

          3. The subjects should be willing to comply with the study procedure and schedule,
             including the follow up visits, and will refrain from using any other or similar
             treatment technologies (i.e., Laser, RF, IR) for the facial condition.

          4. The subjects will carry on with their usual diet and exercise and will not have a
             significant weight change during the study.

          5. The subject is able to read the User Manual in English.

          6. Subjects should have II-VI Fitzpatrick wrinkle score as indicated on the Fitzpatrick
             Wrinkle and Elastosis Scale (see Table 1).

          7. Negative results in a urine pregnancy test.

        Exclusion Criteria:

          1. Pacemaker or internal defibrillator, or any other active electrical implant anywhere
             in the body.

          2. Permanent implant in the treated area such as metal plates and screws, silicone
             implants or an injected chemical substance.

          3. Current or history of skin cancer, or current condition of any other type of cancer,
             or pre-malignant moles per investigator's discretion.

          4. Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled
             hypertension, and liver or kidney diseases per investigator's discretion.

          5. Pregnancy or nursing, as well as 3-6 months post-childbirth.

          6. History of bleeding coagulopathies, or prolonged use of anticoagulants (daily aspirin
             dosing of 81 mg is acceptable).

          7. Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use
             of immunosuppressive medication per investigator's discretion.

          8. Subjects with history of diseases stimulated by heat, such as recurrent Herpes Simplex
             in the treatment area, may be treated only following a prophylactic regime.

          9. Poorly controlled endocrine disorders, such as diabetes or thyroid abnormality per
             investigator's discretion.

         10. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash
             per investigator's discretion.

         11. History of skin disorders, keloids, abnormal wound healing, as well as very dry and
             fragile skin per investigator's discretion.

         12. Any surgery in treated area within 3 months prior to treatment or before complete
             healing.

         13. Injected fillers in the last 6 months and Botox in the last week.

         14. Use of Isotretinoin (AccutaneÂ®) within 6 months prior to treatment.

         15. As per the practitioner's discretion, refrain from treating any condition that might
             make it unsafe for the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

